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Interleukin-3 (IL-3) promotes both self-renewal and differen-
tiation of early multipotential progenitors and is involved in
inducible hematopoiesis in response to infections. Here we
report new insights into these processes with the identification
of a new isoform (SP2) of IL-3 receptor  (IL-3R), present in
mouse and human hematopoietic cells, which lacks domain 1 of
the full-length receptor (SP1). Binding assayswithIL-3mutants
showed that mouse SP2 uses a different high affinity binding
mode to SP1, although bothmouse and human SP2 and SP1 can
stimulate IL-3-dependent growth. In IL-3-dependent differen-
tiation models, human SP2 and SP1 gave differential effects on
lineage commitment or self-renewal dependent on the cellular
context, suggesting that different modes of ectodomain binding
may modulate intracellular signaling. In a multipotential factor
dependent cell-Paterson mix, the transcription factors C/EBP
and PU.1 and microRNAs miRNA-15a, -223, and -181a were
up-regulated in cells undergoing SP2-supported differentiation
compared with SP1-supported self-renewal. Similarly in M1
cells, SP2promoteddifferentiation comparedwith SP1 andgave
up-regulation of PU.1 andmiRNA-155 and -223. These findings
suggest that IL-3-promoted lineage commitment uses similar
mechanisms to those of steady-state hematopoiesis. Both the
SP1 and SP2 isoforms activated the Jak2/STAT5, Akt, and
Erk1/2 signaling pathways in M1 cells, although the activation
was more prolonged for the SP2 isoform.
IL-32 is a multipotent cytokine affecting all steps in myeloid
differentiation (1–4). It promotes the self-renewal of earlymul-
tipotential cells, the proliferation and differentiation ofmyeloid
progenitors, and the survival and activation of mature cells.
IL-3 is mainly produced by activated T lymphocytes and mast
cells suggesting a role in inflammation and responses to infec-
tions. It appears to have a unique role in relation to plasmacy-
toid dendritic cells (5) and basophils (6), which have important
roles in both innate and adaptive immunity. Studies of IL-3-
deficient mice demonstrate that IL-3 is required for the eleva-
tion of mast cells and basophils in response to parasite infec-
tions (7). The IL-3R is overexpressed on leukemic stem cells
and blasts suggesting a role in leukemia pathogenesis (8–10).
IL-3 signaling in humans is mediated by a receptor system
(IL-3R) composed of an IL-3-specific  receptor and a  recep-
tor (hc) that is shared with two related cytokines, IL-5 and
GM-CSF (11–14). In mice, there is a shared c (mc) receptor
but also an IL-3-specific  receptor (IL-3) (15). Both  recep-
tors require the mouse IL-3R (mIL-3) for activation (16).
Upon receptor activation, the cytoplasmic portions of the 
receptors, which lack any intrinsic kinase activity, initiate a
number of signaling pathways, including the Janus kinase 2/sig-
nal transducers and activators of transcription, phosphatidyl-
inositol 3-kinase, and Ras/mitogen-activated protein kinase
pathways (17). Previous studies of IL-3 signaling have mainly
concentrated on growth and reversal of apoptosis, whereas the
mechanisms regulating differentiation and self-renewal remain
poorly understood. It remains controversial whether cytokine
receptors in general can play an instructive role in lineage spec-
ification in hematopoiesis, and steady-state blood cell forma-
tion appears to largely involve stochastic processes (18). How-
ever, there is evidence that the GM-CSF receptor (GM-CSFR)
can play an instructive role in the differentiation ofmultipoten-
tial cells (19).
The IL-3R is amember of the cytokine class I receptor family
(20). One of the best studied members of this family is the
growth hormone receptor, which illustrates the basic principles
of receptor activation. Ligand binding with the growth hor-
mone receptor occurs at the elbow region formed between the
two domains of the cytokine receptor homology module, and
activation involves homodimerization. In contrast, we have
shown the ectodomain of the hc receptor to be a novel inter-
twined homodimer (21); an unexpected departure from other
structures of the family. However, the hc receptor has a
ligand-binding elbow region analogous to that of the growth
hormone receptor, although it is composed of domains 1 and 4
of the two different protein chains (22–24). The homologous
mouse IL-3 receptor is also a homodimer, and its elbow
region forms the direct IL-3 binding site (22). Surprisingly,
however, high affinity IL-3 binding by the IL-3-IL-3R com-
plex does not involve the residues of the direct IL-3 binding
site (22). The IL-3 receptor therefore represents an interest-
ing departure from the canonical activation mechanisms
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established for receptors like the growth hormone and eryth-
ropoietin receptors.
In the present work we have identified a new ectodomain
isoform of IL-3R, designated SP2, which is present in mouse
and human hematopoietic cells. Unlike the previously charac-
terized (SP1) isoform, mIL-3R SP2 utilizes the direct IL-3
binding region of IL-3 for high affinity binding and signaling
showing that the IL-3 receptor has two alternative modes of
receptor activation via the SP1 and SP2 isoforms. Thus the IL-3
receptor is similar to the fibroblast growth factor (FGF) recep-
tor, in that it utilizes ectodomain isoforms which modulate
receptor function (25).
Herein, we show that IL-3 receptor activation via the mouse
and human SP1 or SP2 IL-3R isoforms gives growth signaling
in the presence of the appropriate receptor. However, the two
isoforms show differential effects on self-renewal and lineage
commitment dependent on the cellular context. This suggests
that the mode of ectodomain engagement can modulate intra-
cellular signaling by identical cytoplasmic receptor chains as
has been suggested recently for the activation of IL-4R/IL-
13R1 heterodimers by IL-4 or IL-13 (26). The elevation in
expression of particular transcription factors and microRNAs
(miRNAs) in cells undergoing IL-3R SP2-supported diffe-
rentiation, compared with cells undergoing SP1-supported
growth/self-renewal, indicates that the mechanisms involved
are similar to those found in steady-state blood cell formation.
The demonstration of the existence and activity of the SP2 iso-
form reveals additional complexity in IL-3R signaling and pro-
vides valuable insights into how an individual growth factor can
initiate many distinct cellular outcomes.
EXPERIMENTAL PROCEDURES
Cells and Cell Culture—Unless otherwise stated the cytokines
used for cell culture were produced in Hi5 insect cells grown in
serum-free medium. For differentiation assays with cells express-
ing the hIL-3R, hIL-3 was used at 220 units/ml and, where added,
mIL-3 at 0.4 units/ml. For cells expressing the hGM-CSFR, hGM-
CSF was used at 290 units/ml. For differentiation of parental
FDCP-mix cells, mGM-CSF was included at 0.1% v/v. Details of
the media used are given in the supplemental materials. Mouse
eosinophils (99% purity) were isolated from white blood leuko-
cytes prepared from spleens of IL-5 transgenic mice using a BD
FACSVantage SE cytometer and gating on forward scatter and
side scatter. Mouse mast cells and B lymphocyte blasts were gifts
fromS.Gustin (University ofWesternAustralia) andC.Goodnow
(Australian National University), respectively.
DNA Constructs and Stable Transfection—Mouse and
human IL-3R SP2 cDNAs andDNA constructs ofmouseIL-3
point mutations were derived from their respective SP1 forms
or mouse IL-3 using the QuikChange protocol (Stratagene)
with Pfu Turbo DNA polymerase and verified by DNA
sequencing. cDNAs encoding mouse and human IL-3R SP1
and SP2 and hGM-CSFR were cloned into the pEFIRES-N
(G418) or pEFIRES-H (hygromycin B) expression vector and
cDNAs for mc, hc, or mIL-3 cloned into pEFIRES-P (puro-
mycin). cDNAs were cloned into the pcEXV-3 vector (23) for
COS7-based binding assays. Transfection details are given in
the supplemental materials. As many as possible stable trans-
fectants were recovered, yielding polyclonal populations of
cells.
miRNA Preparation and Quantification of miRNAs and
Transcription Factors—miRNA was prepared from M1 and
FDCP-mix cells expressing human IL-3R SP1 or SP2 plus hc
and grown under conditions permitting differentiation using
an miRNeasy mini kit (Qiagen). The detection and quantifica-
tion of miRNAs was carried out by quantitative real-time RT-
PCRwith themiScript system (Qiagen) and 7500Real timePCR
system (Applied Biosystems). Quantitative real-time PCR was
also used to detect and quantify mRNA-encoding transcription
factors from the same miRNA preparation in M1 and FDCP-
mix cells (see supplemental materials).
RT-PCR, Deglycosylation, and Western Blot Analysis—De-
tection of mouse and human IL-3R SP1 and SP2 in mouse or
human cells was conducted by RT-PCR and/or Western blot
analysis. Deglycosylation of mouse IL-3R SP1 and SP2 was
performed by treatment with peptideN-glycosidase F.Western
blot analysis was also performed to examine the expression of
transcription factors inM1 cells. For details see the supplemen-
tal materials.
Proliferation Assays—Growth responses of CTLL-2,M1, and
FDCP-mix cells expressing IL-3R and/or relevant  subunit
receptors to hIL-3 or mIL-3 were measured in triplicate by
[3H]thymidine incorporation as described previously (23). For
CTLL-2 cells, proliferation was measured after 2 days of incu-
bation and for M1 and FDCP-mix after 4–5 days. Growth
assays for WEHI 3B D cells were conducted by counting the
viable cell number with trypan blue exclusion under the light
microscope.
Flow Cytometry—M1 andWEHI 3B D cells expressing the
appropriate human receptors were incubated with or with-
out hIL-3 (220 units/ml) or hGM-CSF (290 units/ml) for 4
days in growth medium. Similarly, FDCP-mix cells were
incubated with hIL-3 (220 units/ml) with or without low
mIL-3 (0.4 unit/ml), or incubated with lowmIL-3 or 0.1% v/v
mouse GM-CSF for 6 days. The expression of surface mark-
ers and IL-3R subunits was examined by flow cytometry (see
supplemental materials).
Binding Assays—COS7 cells were transiently transfected
withmouse IL-3R SP1 or SP2withwild-type ormutantmouse
IL-3 constructs. Two days after transfection, the COS7 cells
were harvested and binding assays were done as described pre-
viously (22).
Morphological Analysis—Details of light and electron
microscopy are given in the supplemental materials.
Analysis of Signal Transduction Pathways—Phosphorylation
of Jak2, STAT5, Akt, and Erk1/2 was investigated in M1 cells
expressing hIL-3R and hc. Details of phosphorylation anal-
ysis andWestern blot are shown in the supplemental materials.
Statistical Analysis—AStudent’s two-tailed non-paired t test
was used to determine the statistical significance.
RESULTS
ANew Isoform IL-3R
We identified previously unrecognized alternatively spliced
isoforms of the IL-3R among the mRNA sequences in the
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NCBI expressed sequence tag databases inmouse (GI:5599968;
from a placental library) and human (GI:19018027; from a ret-
inal pigment epithelium and choroid library), which we desig-
nated SP2. The new SP2 isoforms lack domain 1 of the extra-
cellular region due to precise deletion of exons 3 and 4 of the
gene (Fig. 1, A and B). The additional sequence available from
the trace archive indicated that apart from deletion of domain
1, the SP2 isoformswere otherwise identical with the previously
characterized SP1 isoform (16).
Measurement of expression of the SP2 isoforms in mouse
hematopoietic cells by RT-PCR showed thatmRNA for the SP2
isoformwas readily detectable in a variety of hematopoietic cell
lines and in eosinophils, mast cells, and B lymphocyte blasts
(Fig. 2A), although it was expressed at a lower level than the SP1
form. Clones encoding the SP2 isoforms were isolated and
sequenced from mouse FDCP-1, FDCP-mix, WEHI-3B, and
GB2 cells and shown to conform to the structure in Fig. 1. We
also examined IL-3R isoform protein levels in mouse cells by
Western blotting. The sizes of the receptor bands indicated
extensive glycosylation (five potential N-glycosylation sites in
SP1 and four in SP2). Deglycosylation was carried out on the
samples to simplify analysis, and bands corresponding to the
predictedmolecularmasses of themature SP1 and SP2 proteins
(41 and 31 kDa, respectively) were demonstrated in a variety of
mouse cell lines (Fig. 2B). The mIL-3R SP1 protein was the
major form detected in FDCP-1, WEHI-3B, and GB2 cells,
although inmultipotential FDCP-mix cells the levels of SP2 and
SP1 proteins weremore comparable. Although low levels of the
SP2 form were detected by RT-PCR in the M1 myeloblastic
leukemia cell line, no SP2 protein was detected by Western
blotting. Similarly in FDCP-mix, the marked differences
between relative RNA and protein levels suggested the exist-
ence of translational controls affecting SP1 and SP2 levels.
Without deglycosylation, the majority of samples showed
receptor bands of54 and 41 kDa consistent with glycosylated
SP1 and SP2 isoforms. In WEHI-3B cells the receptor was of
much higher molecular mass, but deglycosylated samples gave
similar receptor sizes to the other cell lines (Fig. 2B).
Expression of the human IL-3R (hIL-3R) SP2 isoform
was demonstrated in a variety of human leukemia lines by
RT-PCR. hIL-3R SP2 isoform expression was lower than
the SP1 form, a finding analogous to the results from mouse
(Fig. 2C). Clones encoding the SP2 isoform were isolated and
sequenced from human TF-1 cells and shown to conform to
the structure in Fig. 1.
Growth Signaling by theMouse and Human IL-3R SP2
Isoforms
To test the ability of the SP2 isoform to function in growth
signaling, the mIL-3R SP2 isoform was expressed in CTLL-2
cells with and without IL-3 or mc. Similarly, the hIL-3R SP2
FIGURE 1. Structure of the SP2 isoform of mouse and human IL-3R.
A, schematic models of IL-3R SP1 and SP2 isoforms showing the structural
domains. B, DNA and protein sequence covering the N-terminal region of
human and mouse IL-3R SP2 showing the position of the deletion of exons
3 and 4, which encode domain 1 of the extracellular region (indicated by the
arrows). The start of themature protein sequence (predicted by SignalP 3.0) is
shown bold and underlined. The full-length nucleotide sequences have been
submitted to GenBankTM with accession numbers of FJ550346 for mouse
IL-3R SP2 and FJ550347 for human IL-3R SP2.
FIGURE 2.Detectionofmouse andhuman IL-3RSP1andSP2 isoforms in
hematopoietic cells. A, RT-PCR analysis of mIL-3R isoforms in mouse cells.
Predicted sizes: SP2, 200 bp; SP1, 479 bp. CTLL-2 cells expressing mouse SP2
(mSP2) or mSP1 were used as positive controls, no cDNA sample as PCR neg-
ative control, mouse -actin as internal control.D/D: with/without differ-
entiation capacity. B, Western blot analysis of mIL-3R SP2 and SP1 inmouse
cells. CTLL-2 cells transfected with mSP2 or SP1 were used as positive con-
trols. Proteins sampleswere analyzedwith () orwithout () deglycosylation
(dg) treatmentusingpeptideN-glycosidaseF (PNGase F). Resultswereverified
in at least two independent experiments. C, RT-PCR analysis of hIL-3R iso-
forms in human cell lines. Predicted sizes: SP2, 167 bp; SP1, 401 bp. FDCP-mix
cells expressing human SP2 (hSP2) or hSP1 were used as positive controls,
human -actin as internal control.
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isoform was expressed in CTLL-2 with and without hc.
CTLL-2 is an IL-2-dependent mouse cytotoxic T cell line that
does not express the mIL-3R, IL-3 or mc receptors. Expres-
sion of the relevant receptor proteins was verified by FACS
(supplemental Figs. S1 and S2A). In the case of the mIL-3R
SP2 isoform, we were unable to find a suitable antibody for
detection by FACS, and Western blotting was used to verify
expression (supplemental Fig. S2B).
We found that mIL-3 stimulated
growth signaling of CTLL-2 cell
lines expressing mIL-3R SP2/
IL-3, but that higher levels were
required than for the receptor sys-
tem involving the SP1 form to
achieve half-maximal stimulation
(Fig. 3A). CTLL-2 cells expressing
the SP2 form alone were unrespon-
sive to mIL-3, even at concentra-
tions of 480 units/ml. Interestingly,
mIL-3R SP2 was shown to signal
specifically with IL-3 and could not
signal with mc (Fig. 3B). Similarly,
CTLL-2 cells expressing hIL-3R
SP2/hc gave full growth signaling
in response to hIL-3, but also
required higher levels of hIL-3 than
the receptor system involving the
SP1 form to achieve half-maximal
stimulation (Fig. 3C). CTLL-2 cells
expressing the hIL-3R SP2 form
alone were unresponsive to hIL-3,
even at doses of 1795 units/ml. In a
previous study on hIL-3R, where
domain 1 was deleted by mutagene-
sis to yield a receptor similar (but
not identical) to the naturally occur-
ring SP2 isoform studied here, a
requirement for higher levels of IL-3
to give full growth was also observed (27).
The Canonical IL-3 Binding Site onIL-3 Is Utilized bymIL-3R
SP2 but Not SP1
The mIL-3R SP1 or SP2 isoform was co-expressed with
IL-3 in monkey COS7 cells, and radioiodinated IL-3 was used
to determine the binding constants for high affinity binding.
Consistent with previous studies, theKd formIL-3R SP1/IL-3
high affinity IL-3 binding was200 pM (22, 23). In contrast, the
Kd for mIL-3R SP2/IL-3 was found to be 750 pM (Fig. 4,A and
B, and Table 1). These findings are broadly consistent with the
relative levels ofmIL-3 required for growth signaling by the SP1
and SP2 isoforms in CTLL-2 cells described above.
IL-3 receptors carrying individual mutations in the residues
comprising the direct IL-3 binding site were also tested. Our
previous, detailed studies have shown that mIL-3 high affinity
binding is not significantly affected by any of the IL-3 muta-
tions that abolish direct IL-3 binding when co-expressed with
mIL-3R SP1 (22, 23). Consistent with these studies, we show
in the present work that mIL-3 high affinity binding with IL-3
Y21A (Tyr21 3 Ala)/mIL-3R SP1 was similar to that of the
wild-type IL-3 receptor (Table 1). In contrast, mIL-3R SP2
high affinity binding was abolished by the Y21A mutation
within IL-3. Indeed, each of the IL-3 residues that mediate
direct mIL-3 binding (Tyr21, Phe85, Asn87, Ile320, Tyr348, and
Tyr401) were critical for high affinity bindingwithmIL-3R SP2
(Table 1), indicating that the SP1 and SP2 isoforms have differ-
ent mechanisms of high affinity binding. To verify this finding
FIGURE 3.Growth signaling bymouse and human IL-3R SP1 and SP2 isoforms. A, CTLL-2 cells expressing
mIL-3R SP2 or SP1 andIL-3. B, CTLL-2 cells expressingmIL-3R SP2 or SP1 andmc.C, CTLL-2 cells expressing
hIL-3R SP2 or SP1 and hc. Cells were grown inmedia supplementedwith various concentrations ofmIL-3 or
hIL-3 as indicated for 2 days and growth measured in triplicate by [3H]thymidine incorporation in at least two
independent experiments. Data are means; error bars are standard deviations.
FIGURE 4. Scatchard plots of mIL-3 binding assays and growth signaling by mouse Y21A mutant IL-3.
A and B, Scatchard representation of 125I-labeled mIL-3 hot saturation binding data for COS7 cells transiently
transfected with mIL-3R SP1 (A) or SP2 (B) and IL-3 for 2 days. C, growth assay of CTLL-2 cells expressing
mIL-3R SP2 or SP1 and Y21Amutant IL-3. Cells were grown inmedia supplemented with various concentra-
tionsofmIL-3or hIL-3 as indicated for 2days andgrowthmeasured in triplicateby [3H]thymidine incorporation
in at least two independent experiments. Data representing at least three independent experiments are
means; error bars are standard deviations.
TABLE 1
Dissociation constants for mIL-3 binding to COS7 cells expressing
mIL-3R isoforms and wild-type or mutant IL-3 subunits
IL-3
Location of
mutation mIL-3R
No.
sites Kd S.E.
a No.
experiments
pM
Wild type SP1 1 199 16 3
2 235 15 7
Wild type SP2 1 710 20 4
2 783 54 3
Tyr213 Ala A-B loop SP1 1 310 7 2
Tyr213 Ala A-B loop SP2 -b 3
Phe853 Ala E-F loop SP2 - 3
Asn873 Ala E-F loop SP2 - 4
Ile3203 Ala Interdomain SP2 - 2
Tyr3483 Ala B-C loop SP2 - 4
Tyr4013 Ala F-G loop SP2 - 3
a TheKd S.E. was determined using the hot saturation binding assay, and the data
were analyzed using KELL RADLIG and LIGAND.
b The hyphen indicates no binding detected above the background non-specific
binding.When a two-sitemodel was found to be statistically significant (p 0.05),
the low affinity siteKdwas fixed as 45 nM to obtain amore accurate estimate of the
Kd for high affinity binding. The Kd values for high affinity binding for mIL-3R
SP1 and IL-3 Phe853 Ala, IL-3 Asn873 Ala, IL-3 Ile3203 Ala, IL-3 Tyr3483
Ala, and IL-3 Tyr4013 Ala are all similar to those for wild-type IL-3 and were
reported previously (22).
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in terms of growth signaling, stable transfectants of CTLL-2
expressing IL-3 Y21A and either the mIL-3R SP1 or SP2 iso-
forms were prepared and tested for IL-3 growth stimulation.
The Y21AIL-3 mutation blocked growth signaling by themIL-
3R SP2 isoform but did not affect that by mIL-3R SP1 (Fig.
4C). Receptor expression was verified by FACS and Western
blotting (supplemental Fig. S2,A andB). These findings provide
strong support for the existence of two different modes of IL-3
receptor activation involving the two ectodomain isoforms of
mIL-3R.
Activity of the hIL-3R Isoforms in Differentiation
In vitromodels of hIL-3-supported granulocyte/macrophage
differentiation have not previously been established. However,
because hIL-3 does not cross-react with the mIL-3 receptor
system, ectopic expression of the human IL-3R isoforms in
mouse cells allows testing of their role in differentiation. We
established hIL-3 differentiationmodels in FDCP-mix,M1, and
WEHI-3B D cells.
hIL-3R in Differentiation of FDCP-mix Cells—FDCP-mix is
a non-leukemogenic multipotential myeloblastic cell line,
which has a normal karyotype and grows continuously in an
undifferentiated state in high concentrations of mIL-3 (28). In
the presence of low levels ofmIL-3, FDCP-mix can differentiate
into neutrophils, monocytes, erythrocytes, or dendritic cells
depending on the cytokines provided in the medium. FDCP-
mix is thus capable of self-renewal or cytokine-supported dif-
ferentiation and has the properties expected for an immortal-
izedmultipotential hematopoietic progenitor. It has previously
been shown that, when FDCP-mix is transfected with hGM-
CSFR and hc, hGM-CSF supports granulocyte/macrophage
differentiation comparable to that achieved with mGM-CSF in
parental cells (29). Thus hc can interact effectively with the
mouse signaling machinery involved in mGM-CSF supported
differentiation.
To verify the capacity of FDCP-mix for cytokine-directed
differentiation, we treated parental cells with mGM-CSF and
obtained differentiation to neutrophils andmonocytes (Fig. 5A)
in agreement with previous findings (19). Evaluation of surface
markers by FACS showed significant increases in expression of
Mac-1 and Gr-1 but little increase in Mar-1 (FcRI) when
compared with cells treated with low levels of mIL-3 (Fig. 5B),
consistent with the differentiation observed. With FDCP-mix
cells expressing hIL-3R SP2 isoform and hc, in the presence
of low levels ofmIL-3, hIL-3 induced differentiation, whereas in
the absence of mIL-3 the cells died (Fig. 5C). When hIL-3R
SP2 was expressed alone in FDCP-mix cells, hIL-3 did not
induce differentiation. In FDCP-mix cells co-expressing hIL-
3R SP1 and hc, hIL-3 stimulated growth but no differentia-
tion, in the presence or absence of low levels of mIL-3 (Fig. 5C).
The lack of differentiation activity of the hIL-3R SP1 isoform
is an unexpected result, but our results agree with a previous
detailed study that included clonogenic assays and showed that
the hIL-3R SP1 isoform only promoted self-renewal in FDCP-
mix cells (29). The expression of the introduced receptors was
verified by FACS in all cases (supplemental Fig. S1).
May-Grunwald-Giemsa staining showed that the differenti-
ation achieved by the hIL-3R SP2 isoform was novel. The
majority of differentiated cells appeared to be basophil-like
with lobulated nuclei partially obscured by granules (Fig. 5A)
(30, 31). In contrast to the cells resulting frommouseGM-CSF-
stimulated differentiation, the expression of Mac-1 and Gr-1
was not increased in the hIL-3 differentiated progeny (Fig. 5B),
and they did not express c-Kit or B220 (data not shown). CD49b
(DX5) expression was slightly increased, and FcRI (Mar-1)
was very slightly elevated. Although Mar-1 is typical of
basophils andmast cells, previous evidence has shown that high
levels of expression requires the presence of IgE, which is
absent from our in vitro differentiation conditions (32, 33). The
lobulated nuclei evident by light microscopy and the lack of
increase of c-Kit expression determined by FACS suggested the
differentiated FDCP-mix cells were basophils (30, 31, 34). To
further confirm their identity, the differentiated cells were
examined by electron microscopy (Fig. 5D). The lobulated
nuclei in the cells were verified, and a number of electron-dense
staining granules were evident. The electron microscopy gave
further support that the cells were basophil-like (35, 36). Inter-
estingly, the cells appeared to be undergoing extensive degran-
ulation by mechanisms involving individual granules and gran-
ules organized into large degranulation chambers (Fig. 5D).
Bothmechanisms have been described in detail previously (36).
hIL-3R in Differentiation of M1 Myeloblastic Leukemia
Cells—The ability of the hIL-3R SP1 and SP2 isoforms to pro-
mote differentiation was also tested using the mouse myelo-
blastic leukemia line, M1. This cell line proliferates independ-
ently of growth factors, has a blast-like morphology, and has
been previously used for differentiation assays in response to
human GM-CSF (hGM-CSF) (37). For comparison, we used
M1 cells expressing hGM-CSFR and hc and showed these
cells could be differentiated into monocytes/macrophages by
hGM-CSF (Fig. 6A). This activity required the presence of the
hc receptor. Differentiation was shown by changes in mor-
phology and increased expression of the surfacemarkersMac-1
and F4/80 (Fig. 6, A and B). At high concentrations of hGM-
CSF, cessation of growth was observed (data not shown). Our
findings with hGM-CSF differentiation of M1 cells are in good
agreement with a previous study (37). When hIL-3R SP2 was
co-expressed in M1 with hc, hIL-3 also promoted differentia-
tion to monocytes/macrophages, and again this activity was
dependent of the presence of hc. At high concentrations of
hIL-3, cessation of growth was evident (data not shown). The
changes inmorphology, increases in surfacemarker expression,
and cessation of growth induced by hIL-3 and hGM-CSF were
quite similar (Fig. 6, A and B). In contrast, when analogous M1
cell lines containing the hIL-3R SP1 isoform were examined,
hIL-3 stimulated none of the changes observed for SP2,
although a slight increase in F4/80 expression and a slight
reduction of growth was detected. The expression of the intro-
duced receptors was verified by FACS (supplemental Fig. S1).
The activity of the hIL-3R SP2 isoform in the presence of hSP1
was tested in M1 cells by ectopically expressing both receptors
together with hc. In these circumstances the hSP2 isoform
still supported differentiation but there were differences com-
pared with SP2 alone. Although there was a significant increase
in F4/80, there was no detectable increase in Mac-1. Also, the
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differentiated cells appeared less
mature (supplemental Fig. S3).
hIL-3R in Differentiation of
WEHI-3B Myelomonocytic Leuke-
mia Cells—WEHI-3B D is a
mouse myelomonocytic cell line
capable of monocytic differentia-
tion. Previous studies have shown
that the differentiation ofWEHI-3B
D cells expressing hGM-CSFR/
hc intomonocytes is stimulated by
hGM-CSF (37), and we verified this
finding in our experiments (Fig. 7A).
hGM-CSF also promoted elevated
expression of Mac-1 and F4/80 (Fig.
7B), consistent with the differentia-
tion into monocytes. Either hIL-
3R SP1 or SP2 was introduced in
combination with hc, and the
expression of the exogenous recep-
tors was verified by FACS (supple-
mental Fig. S1). In contrast to
FDCP-mix andM1 cells, the human
SP1 isoform and not the SP2 iso-
form was the most active in sti-
mulating the differentiation of
WEHI-3B D cells into monocytes
(Fig. 7A). Morphological differenti-
ation was associated with elevated
expression of Mac-1 and F4/80 (Fig.
7B) and a reduction in cell numbers
(Fig. 7C). Thus in the three different
models, the human IL-3R SP1 and
SP2 isoforms showed differential
activity in supporting differentia-
tion dependent on the cellular con-
text and signaling environment.
Mechanisms of hIL-3-supported
Differentiation
It was of interest to determine
whether IL-3 signaling promoted
differentiation by similar mecha-
nisms to those established for
steady-state blood cell formation.
A variety of studies of normal
hematopoiesis has shown that lin-
eage determination is the result of
the combinatorial action of several
transcription factors (38). Addi-
tionally, there is growing evidence
of the important role of miRNAs
in regulating hematopoietic differ-
entiation (39, 40). We studied the
changes in the expression of rele-
vant transcription factors and
miRNAs in FDCP-mix, because
this is a non-leukemic multipoten-
FIGURE 5. Effect of hIL-3R SP2 and SP1 isoforms on the differentiation of FDCP-mix cells in response to
hIL-3. Responses to hIL-3 of cells expressing the hIL-3R SP1 or SP2 isoformswith andwithout hc after 6 days
culture were compared with responses of parental cells to mGM-CSF. A, morphological examination by light
microscopyafterMay-Grunwald-Giemsa staining. Scale bar10m.B, representative FACSanalysis of expres-
sion of the surface markers, Mac-1, Gr-1, CD49b (DX5), and FcRI (Mar-1). C, growth responses measured by
[3H]thymidine incorporation in triplicate. Data are means; error bars are standard deviations. D, electron
microscopy of basophil-like cells generated by hIL-3R SP2 signaling. The left side image shows individual
electron dense granules at different stages of degranulation (filled arrowheads), whereas the right side image
shows large degranulation chambers (arrows) withmultiple granules undergoing degranulation. Results were
verified in at least two independent experiments.
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tial cell line, but also carried out more limited studies on M1
cells for comparison.
Induced Changes in Transcription Factor Expression
In FDCP-mix cells, transcription factor mRNA levels were
measured using quantitative real-time PCR with hypoxan-
thine-guanine phosphoribosyltransferase as control after 4
days of treatment with hIL-3 under differentiation conditions
(Fig. 8A). FDCP-mix cells expressing hIL-3R SP2/hc and dif-
ferentiating to basophils were compared with cells expressing
hIL-3R SP1/hc and undergoing self-renewal. In differentiat-
ing cells, mRNA for the transcription factor C/EBP was
increased 3-fold, and smaller increases in C/EBP and PU.1
were also detected. C/EBP is established as the master regula-
tor of steady-state granulopoiesis and also regulates commit-
ment of basophil progenitors to the basophil lineage (30).
C/EBP has been shown to be involved in emergency granulo-
poiesis (41), and PU.1 is involved in granulocyte and macro-
phage differentiation (42). In contrast, NFYA, Id1, and c-Myb
were down-regulated, consistent with their role in promoting
self-renewal (43–45). The same changes were also observed
when UBC (ubiquitin-conjugating enzyme E2D) was used as
control (data not shown).
Elevated expression of the transcription factor PU.1 has been
shown to be functionally important in promoting monocyte/
macrophage differentiation, whereas an increase in GATA-2
expression is important in neutrophil differentiation (46).
UsingWestern blotting, we showed elevated expression of PU.1
in M1 cells directed along the
monocyte differentiation pathway
by hIL-3 signaling via the SP2 iso-
form. In contrast, the expression
of GATA-2 was not significantly
changed (Fig. 8B).
Induced Changes in Expression of
miRNAs
The levels of eight miRNAs
known to be involved in the re-
gulation of differentiation and
hematopoiesis were measured to
determine if miRNAs were likely
to be involved in regulating the
IL-3-supported differentiation of
FDCP-mix (Fig. 8C) and M1 (Fig.
8D). In differentiating FDCP-mix
cells miR-15a, miR-181a, and
miR-223 were noticeably elevated.
Human miR-15a has been shown
to suppress Bcl-2 and to be down-
regulated in B-lineage chronic
lymphoid leukemia (47). In mouse,
miR-181a is up-regulated inmyoblast
differentiation and is involved in lym-
phopoiesis such as B-cell differentia-
tion (48), whereas miR-223 behaves
like a myeloid gene and is up-regu-
lated in myeloid differentiation asso-
ciated with an increase in the levels of PU.1 and C/EBP (49). In
differentiating M1 cells, miR-223 was also elevated, but the other
major increase was inmiR-155, anmiRNA previously reported to
be oncogenic, correlated with granulocyte/monocyte expansion
and induced during themacrophage inflammatory response (50).
Downstream Signaling Pathways Activated by the SP1 and
SP2 Receptors
Preliminary studies of the signaling pathways activated by
the two IL-3R isoforms were carried out in M1 cells. Both
receptors activated the Jak2/STAT5, Akt, and Erk1/2 signaling
pathways. Interestingly, the SP2 receptor gave more prolonged
activation of Jak2,Akt, andErk1/2 (Fig. 8E).More detailed stud-
ies are in progress to try and understand the differences in sig-
naling from the two receptor isoforms.
DISCUSSION
The importance of alternative RNA splicing in the genera-
tion of genetic diversity is now widely accepted. Different
receptor isoforms can have unique properties, and abnormal
overexpression of particular isoforms has been linked to disease
pathogenesis. The alternatively spliced isoforms of the FGF
receptor (51) and of CD44 (52) arewell studied examples. In the
present work we have identified a new ectodomain isoform
(designated SP2) of IL-3R, which is expressed in mouse and
human hematopoietic cells and which lacks the first domain of
the receptor. We have shown that IL-3R SP2 can signal for
IL-3-dependent growth in CTLL-2 cells in the presence of an
FIGURE 6. Effect of hIL-3R SP2 and SP1 isoforms on the differentiation of M1 cells in response to hIL-3.
Responses to hIL-3 of M1 cells expressing the hIL-3R SP1 or SP2 isoforms with and without hc after 4 days
incubation were compared with responses to hGM-CSF of M1 cells expressing hGM-CSFR and hc. A, mor-
phological examination by light microscopy after May-Grunwald-Giemsa staining. Scale bar 10m. B, FACS
analysis of expression of the surface markers, F4/80 and Mac-1. All data are representative at least two inde-
pendent experiments.
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appropriate  receptor. mIL-3R SP2 cannot signal with mc,
but only with IL-3, upon mIL-3 stimulation, raising the possi-
bility that the IL-3 receptor may have a unique function not
fulfilled by mc. Previous investigations have not found any
unique role for this receptor (53), althoughmore detailed stud-
ies on IL-3 functions in immune responses and in inflammation
are required. In the case of the hIL-3R, both the hIL-3R SP1
and SP2 isoforms interact with hc. The question arises as to
whether SP2 isoforms also exist for IL-5R and GM-CSFR.
With hIL-5R, no high affinity binding remainswhen domain 1
is deleted (54), and all three domains contribute to IL-5 binding
(55). The role of domain 1 in GM-CSFR has not been investi-
gated. We were unable to find evidence of analogous SP2 iso-
forms for hIL-5R orGM-CSFR in
the mouse and human expressed
sequence tag databases.
Mutation of the IL-3 residues
involved in direct IL-3 binding
enabled us to show that the mIL-
3R SP1 and SP2 isoforms have dif-
ferent mechanisms for receptor
activation. High affinity binding
with mouse IL-3R SP2 requires
each of the residues ofIL-3 involved
in direct IL-3 binding. In contrast,
activation of the receptor by mIL-
3R SP1 does not involve the direct
binding site. This difference is
exemplified by the Y21A mutant of
IL-3, which gives normal growth
signaling with mIL-3R SP1, but is
unable to signal with mIL-3R SP2
upon mIL-3 stimulation. The mIL-
3R SP2 isoform provides a ration-
ale for the existence of the direct
IL-3 binding site onIL-3, whichwas
previously a puzzle because it ap-
peared to play no part in IL-3 signal-
ing with the SP1 isoform.
The ectodomain isoforms of the
IL-3 receptor share some similari-
ties with those of the FGF receptor.
The FGF receptor is composed of
three Ig-like domains, with domains
2 and 3 forming an FGF binding
region. Through alternative splicing
affecting the C-terminal half of
domain 3, each of the Fgfr1–3 genes
generates two ectodomain isoforms
with distinct FGF binding specific-
ity, tissue-specific expression, and
biological response (51). In the case
of IL-3R, domain 1 is an Ig-like
domain and domains 2 and 3 consti-
tute the classic cytokine receptor
homology module, which typically
binds ligand at the elbow region.
Very recently, structures of the
IL-13/IL-4 receptor complexes have shown the nature of the
cytokine-receptor interactions involving both the Ig domain
and domains 2 and 3 of IL-13R1 (26). An important concept
arising from the work with the IL-13/IL-4 receptor system is
that different ectodomain interactions (via IL-13 and IL-4)
with the same receptor system can give different signaling
outcomes (26). As discussed below, we have shown that the
SP1 and SP2 ectodomain isoforms of hIL-3R interacting
with IL-3 and hc can also give different signals raising inter-
esting questions as to the mechanisms involved.
The lack of cross-species activity of hIL-3 in mouse cells
enabled us to investigate the signaling properties of the hIL-
3R isoforms in three in vitromodels of cellular differentiation.
FIGURE 7. Effect of hIL-3R SP2 and SP1 isoforms on the differentiation ofWEHI 3BD cells in response
to hIL-3. Responses to hIL-3 of cells expressing the hSP1 or hSP2 isoforms with and without hc after 4 days
incubation were compared with responses to hGM-CSF of cells expressing hGM-CSFR and hc. A, morpho-
logical examination by light microscopy after staining with May-Grunwald Giemsa. Scale bar  10 m.
B, representative FACSanalysis of expressionof the surfacemarkers, F4/80 andMac-1.C, suppressionof growth
onWEHI 3BD cells byhIL-3RSP1andhc in response tohIL-3.Growthassaywasperformedby counting the
cell numbers following trypan blue staining at the end of the differentiation assay. Data are mean from three
independent experiments; error bars are standard deviations, *, p 0.03; **, p 0.0002 by Student’s t test.
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It is significant that both the hIL-3R SP1 and SP2 isoforms
could signal for growth in CTLL-2 cells co-expressing hc, but
there were clear differences in the signaling properties of the
two isoforms in the differentiation models. In FDCP-mix and
M1 cells, the hIL-3R SP2 isoform was active in supporting
lineage commitment. The hIL-3R SP1 isoform did not sup-
port differentiation of either cell line but supported growth
with retention of blast morphology in FDCP-mix, consistent
with previous detailed studies showing promotion of self-re-
newal by this isoform (29). The differentiation of FDCP-mix to
basophil-like cells in the present work is consistent with the
marked effects of IL-3 on the basophil lineage in vivo. In
WEHI-3B cells, the hIL-3R SP1 and SP2 isoforms also had
different signaling properties, but in this case SP1 was active in
supporting differentiation, whereas SP2 was not. Thus, the sig-
naling properties of the two isoforms in these assays are
dependent on the cellular context.
In FDCP-mix cells undergoing hIL-3R SP2-supported dif-
ferentiation, the major up-regulation of C/EBP and the
increase in PU.1 are analogous to the changes in levels of these
transcription factors during steady-state granulopoiesis.
C/EBP plays a primary role in the fate decision ofmouse baso-
phil/mast cell progenitors (30), and PU.1 stimulates monocyte/
macrophage development (42). Id1, NFYA, and c-Myb, which
have been reported to be involved in proliferation, were down-
regulated in SP2-supported differentiation of FDCP-mix cells.
Recently,miRNAs, a class of22-nucleotide non-codingRNAs
were discovered to play important regulatory roles in mamma-
lian hematopoiesis (40). The observed up-regulation of miR-
223 in this study has also been reported to be associated with
up-regulation of PU.1 and C/EBP in steady-state blood cell
formation (49). It is believed that C/EBP has a specific func-
tion in granulopoiesis: replacing nuclear factor I-A on themiR-
223 promoter and up-regulating miR-223 transcription (39).
The increase in miR-223 levels results in down-regulation of
the nuclear factor I-A protein and stimulation of granulocytic
differentiation. Thus, the differentiation promoted by IL-3R
signaling, which may normally be utilized for inducible hema-
topoiesis in response to infections, may employ similar mecha-
nisms to those involved in normal blood cell formation. The
intracellular signaling links from ligand binding to the tran-
scriptional responses involved in IL-3-dependent differentia-
FIGURE8.Signalingmechanisms involved in IL-3 induceddifferentiation.
A, comparison of expression of transcription factors in FDCP-mix cells in
response to hIL-3 using real-time PCR. FDCP-mix cells expressing hIL-3R SP2
and hc after 4 days incubation were compared with hIL-3R SP1 and hc
cells. Mouse hypoxanthine phosphoribosyltransferase was used as reference
gene. B, Western blot analysis of expression of PU.1 and GATA-2 in M1 cells
expressing hIL-3R SP2 and hc after 4 days incubation with hIL-3. Mouse
-actin was used as internal protein loading control. C and D, comparison of
expression of miRNAs in FDCP-mix (C) or M1 (D) cells in response to hIL-3
using real-time PCR. FDCP-mix or M1 cells expressing hIL-3R SP2 and hc
after 4 days incubation were compared with hIL-3R SP1 and hc cells. U6B
small nuclear RNAwasused as referencegene. Resultswere verified in at least
two independent experiments. All data were expressed as relative -fold
expression of transcription factors or miRNAs (R ratio of hSP2/hSP1), R 1
represents the equal expression between hIL-3R SP2 and SP1. E, Western
blot analysis of downstream signaling pathways initiated by the IL-3R iso-
forms. M1 cells expressing hIL-3R SP1 or SP2 and hc were treated under
differentiation conditions with stimulation by hIL-3 at the times indicated.
Following stimulation, the cells were lysed and the lysates subjected to SDS-
PAGE and immunoblotted using phosphospecific antibodies to Jak2, STAT5,
Akt, or Erk1/2. Subsequently the blot was stripped and re-probed with anti-
bodies to Jak2, STAT5, Akt, or Erk1/2 (1); anti- actin antibody as a loading
control (2).
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tion have not yet been defined and are the subject of ongoing
investigations. However, initial investigations of the down-
stream signaling events in M1 cells have shown that both
IL-3R isoforms activate the Jak2/STAT5, Akt, and Erk1/2 sig-
naling pathways. Interestingly, the SP2 isoform givesmore pro-
longed activation of Jak2, Akt, and Erk1/2.
Apart from its role in inducible hematopoiesis, the IL-3R
signaling is involved in many other processes and is implicated
in a number of diseases. IL-3R is overexpressed on leukemic
stem cells and blasts and plays a potential role in leukemia. It is
currently being developed as a target for anti-leukemia therapy
(56, 57). Because the IL-3R in endothelial cells forms a func-
tional complex with VEGFR-2 (58, 59), IL-3 has a potential role
in neoangiogenesis, in asthma, and in solid tumors. IL-3 has
recently been implicated in schizophrenia (60). Activation of
the IL-3 and GM-CSF receptors induces osteopontin expres-
sion providing a link between these receptors and the CD44
receptor system (61, 62). Thus there are many aspects of IL-3R
signaling yet to be understood. The identification of the IL-3R
SP2 isoform, and demonstration of its activity in hematopoietic
lineage commitment, is an important advance in addressing the
long standing conundrumas to howan individual growth factor
initiates many distinct cellular outcomes.
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Supplementary materials and methods 
Cells and cell culture 
Cells were grown in the following media: CTLL-2, RPMI 1640, 10% FCS, 2 mM L-
glutamine, 0.05 mM 2-mercaptoethanol, 0.1% v/v mIL-2; B4.1 (Hox-2.4 mouse 
myelomonocytic cells), DMEM, 10% FCS, 2% mIL-3; 32Dcl23, RPMI 1640, 10%FCS, 
0.1% mIL-3, 2 mM L-glutamine; FDCP-mix, Iscove’s MEM, 20% horse serum, 2% mIL-
3, 0.3% (w/v) NaHCO3, osmolarity adjusted to 0.32 osmol/L; FDCP-1, RPMI 1640, 10% 
FCS, 0.1% mIL-3, 2 mM L-glutamine, 10 mM NaCl, 1 mM sodium pyruvate, 0.124 mM 
monothioglycerol; GB2, high glucose DMEM, 10% FCS, 0.05 mM 2-mercaptoethanol, 
0.1 mM L-asparagine; COS7, WEHI-3B D+/D-, M1 and HL60, DMEM, 10% FCS; TF1, 
RPMI 1640, 10% FCS, 4 mM L-glutamine, 0.1% hIL-3; NB4, THP-1, MEG-01 and 
KG1a, RPMI 1640, 10% FCS, 2 mM L-glutamine. Cells were cultured in 5% CO2 except 
GB2, WEHI-3B D+/D- and M1 which were cultured in 10% CO2. The growth medium 
for all cell lines was supplemented with 60 μg/ml benzylpenicillin, 100 μg/ml 
streptomycin and 10 μg/ml gentamycin.  
 
DNA constructs and transfection 
Transfection of expression constructs into cells was done using a Bio-Rad Gene Pulser 
Xcell Electroporation System with 290 V and 950 μF capacitance for CTLL-2, M1, 
WEHI 3B D+ cells, and 260 V and 1050 μF for FDCP-mix cells. 2 days after 
transfection, selection was carried out using 0.4 mg/ml G418, 0.05 mg/ml hygromycin B 
and/or puromycin at 0.002 mg/ml (CTLL-2), 0.006 mg/ml (M1), 0.003 mg/ml (WEHI 3B 
D+) and 0.001 mg/ml (FDCP-mix). Transient transfection of COS7 cells with 10 μg of 
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mouse IL-3Rα SP1 or SP2 cDNA and 20 μg wild type or mutant mouse βIL-3 or βIL-3 was 
carried out using 200 V and 960 μF. 
 
miRNA preparation and quantification of miRNAs and transcription factors 
miRNA was prepared from M1 and FDCP-mix cells expressing human IL-3Rα  SP1 or 
SP2 plus hβc cultured under conditions permitting differentiation using an miRNeasy 
mini kit (Qiagen). The detection and quantification of miRNAs was completed by 
quantitative real time RT-PCR using the miScript reverse transcription kit, miSript primer 
assays and miScript SYBR green PCR kit (Qiagen). Details of procedures can be found 
in Qiagen’s miScript system handbook. Qiagen’s  Omniscript RT kit and miScript SYBR 
green PCR kit were employed in quantification of transcription factors. Quantitative RT-
PCR was conducted with the 7500 Real time PCR system (Applied Biosystems). The 
PCR conditions were: initial activation step 95oC 15 min, denaturation 94oC 15 sec, 
annealing 55oC 30 sec, extension 70oC 1 min (extension time for transcription factors 
quantitative RT-PCR was 72oC), 40 cycles. The miScript primer assays used in the 
miRNA experiments were: Mm_miR-15a_1, Mm_miR-16_1, Mm_miR-21_1, Mm_miR-
142-3p_1, Mm_miR-155_1, Mm_miR-181a_1, Mm_miR-223_1, Mm_miR-292-3p_1.  
Hs_RNU6B_1 was used as reference gene compatible with both human and mouse 
species). The mouse UBC and HPRT were employed as reference genes for the 
quantitative real time RT-PCR of transcription factors. Details of primers for reference 
genes and transcription factors are listed in Supplementary Table 1 (Table S1). The data 
were analysed using the comparative CT method (ΔΔCT method), then the fold difference 
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of miRNA or transcription factor expression calculated for IL-3Rα SP2 relative to IL-
3Rα SP1. 
 
RT-PCR, deglycosylation and Western blot analysis 
 Total RNA was prepared using a Qiagen RNeasy mini kit. cDNA was synthesized using 
a Qiagen Omniscript RT kit with anchored or non-anchored Oligo(dT)20 primers and 
PCR was performed using a Qiagen HotStarTaq Master mix kit. Conditions used for PCR 
were 30 cycles and 94oC for 30 sec, 54oC (hIL-3Rα) or 61oC (mIL-3Rα) for 45 sec and 
72oC for 1 min using a PTC-200 Peltier thermal cycler (MJ Research, Watertown MA). 
The primers used are listed in the Table S1. The predicted sizes of PCR products for 
mIL-3Rα SP1 and SP2 are 479 bp and 200 bp respectively and for hIL-3Rα SP1 and SP2 
are 401 bp and 167 bp respectively.  
For the Western blot, total protein or membrane protein fractions were prepared 
with CelLytic-M Mammalian Cell Lysis/Extraction Reagent (Sigma C2978) or CelLytic 
MEM protein extraction kit (Sigma CE0050). For deglycosylation, 80 μg of membrane 
protein fraction in 19.5 μl 1x incubation buffer (20 mM sodium phosphate, 0.02% NaN3), 
was treated with SDS (0.1% final) and β-mercaptoethanol (50 mM final), and the 
proteins denatured by heating at 100oC for 5 min. When cool, NP-40 (0.75% final) and 
3U of N-Glycosidase F (PNGase F, Roche) were added and the mixture incubated for 3 
hr at 37oC. Western blotting was performed using an Invitrogen 4-12% NuPAGE Novex 
pre-cast gel system according to the manufacturer’s instructions.   Rabbit anti-mouse IL-
3Rα (sc-681), PU.1 (sc-352), GATA-2 (sc-9008) antibodies and goat anti-rabbit IgG 
HRP (sc-2004) were used (all from Santa Cruz) at a 1:1000 dilution for primary antibody 
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and a 1:20,000 dilution for secondary antibody. Monoclonal anti-β actin (AC-74, Sigma) 
was used at a 1:5000 dilution. 
 
Analysis of signal transduction pathways 
Phosphorylation of Jak2, STAT5, Akt and Erk1/2 was investigated in M1 cells 
expressing hIL-3Rα SP1 or SP2 and hβc. All the antibodies were from Cell Signalling 
(mouse anti-phosphorylated Jak2Tyr1007/1008, STAT5Tyr694, AktSer473, Erk1/2Thr202/Tyr204 and 
anti-Jak2, STAT5, Akt, Erk1/2). M1 cells expressing the relevant human IL-3 receptors 
were treated with hIL-3 at the indicated times under the conditions of the differentiation 
assay. The M1 cells were harvested and washed once with cold PBS with 1mM Na3VO4. 
Then the cell lysates were prepared with the cold RIPA buffer (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM 
EGTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml pepstain A, 1 mM NaF, 1 mM PMSF) at 4oC 
0.5 h and the lysates were cleared by centrifugation at 4oC 100,000xg, 10 min. The 
cleared lysates were subjected to SDS-PAGE using Invitrogen’s Norvex Nupage 
reducing gel system. The Western blot for phosphorylated and total Jak2, STAT5, Akt, 
Erk1/2 was conducted according to the protocol provided by Cell Signalling. After 
probing with the phosphorylated-antibodies, the same blot was stripped and re-probed for 
detection of total proteins and mouse β-actin for loading control. 
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Flow cytometry 
Approx 106 cells were harvested and washed with ice-cold FACS buffer (2% FCS, 
0.02%NaN3 in PBS). For surface staining, cells were stained for 30 min in the dark at 
4oC. The following antibodies were used:  Serotec, F4/80-FITC; Caltag Laboratories, Gr-
1-FITC; eBioscience, Mar-1-PE (FcεRIα); BD Pharmingen, Mac-1-PE, CD45-FITC 
(B220), CD49b-FITC (DX5),  CD117-PE (c-Kit), 7-AAD. Data were acquired on a 
FACSort cytometer and analysed using FlowJo software. 
Two steps of flow cytometry were used to detect the heterogeneously expressed 
human IL-3Rα SP1 or SP2 with human βc in FDCP-mix, M1, WEHI 3B D+ and CTLL-2 
cells, as well as mouse IL-3Rα SP1 or SP2 with mouse βIL-3, or Y21A βIL-3, or βc in 
CTLL-2 cells. Cells were harvested and washed with cold PBS, and then cells were 
incubated with 1:200 dilution of primary antibody in FACS incubation buffer (0.2% 
BSA, 5% FBS in cold PBS) for 1 hr. After 3 washes with FACS washing buffer (0.2% 
BSA in cold PBS), the cells were then incubated with secondary antibody (1: 500 dilution 
of the relevant isotype of IgG or IgM in FITC or PE, 1:2000 dilution of SA-PE) for 0.5 
hr. Cells were washed three times with FACS washing buffer before being subjected to 
FACS. The same concentration of the relevant isotypes of immunoglobin of primary 
antibodies was used as negative control. The primary monoclonal antibodies are: 
MAB301 (for detection of hIL-3Rα SP1 and SP2, R&D Systems), 3D7 (CDw131, for 
detection of hβc, BD Pharmingen), 5B11 (for detection of mIL-3Rα, BD Pharmingen), 
and AIC2 (for detection of mouse βIL-3 , or Y21A βIL-3 , or βc, MBL Medical and 
Biological Laboratories).  
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Morphological analysis 
Light microscopy: M1 cells were cultured on φ25 mm coverslips in growth medium for 4 
days with and without hIL-3 or hGM-CSF. FDCP-mix cells were cultured using a Lab-
Tek II chamber slider system (Nalge Nunc) in differentiation medium (20% FCS, 0.4 
unit/ml mIL-3, 0.32 osmol/L) for 6 days with or without hIL-3 or mGM-CSF (no mIL-3 
added when mGM-CSF used). Cell morphology was examined under a 100x oil objective 
after May-Grunwald-Giemsa staining. Transmission electron microscopy: FDCP-mix 
cells cultured with hIL-3 in differentiation medium for 6 days were fixed with a half 
volume of fixative solution with 2.5% v/v glutaraldehyde, 3.7% w/v paraformaldehyde in 
0.1 M cacodylate buffer containing 4% w/v sucrose overnight at 4oC. The cells were then 
rinsed with cacodylate buffer, post-fixed with 1% OsO4 in 0.1 M cacodylate for 1 hr and 
dehydrated through a graded series of alcohols and acetone after embedding in agar. The 
agar pellets were thin-sectioned after embedding with resin, the sections stained with 
uranyl acetate and lead citrate and examined in a Hitachi H-7100FA electron microscope. 
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Supplementary figure legends 
Fig. S1.   Detection of hIL-3Rα SP2 or hIL-3Rα SP1 and hβc expression in CTLL-
2, FDCP-mix, M1 and WEHI 3B D+ cells by FACS. Figure shows one of at least 
3 independent experiments. MAB301, mouse anti-human CD123 monoclonal 
antibody; 3D7, mouse anti-human CDw131 (hβc) monoclonal antibody. 
 
Fig. S2.   Detection of the expression of mIL-3Rα SP2 or mIL-3Rα SP1 and 
mouse βIL-3 , or Y21A βIL-3 , or βc in CTLL-2 cells by FACS or Western blotting. A. 
Detection of mIL-3Rα SP1 or mouse βIL-3 , or Y21A βIL-3 , or βc in CTLL-2 cells by 
FACS. AIC2, rat anti-mouse βIL-3 /βc monoclonal antibody; 5B11, rat anti-mouse 
IL-3Rα monoclonal antibody.  B. Detection of mIL-3Rα SP2 expression by 
Western blot analysis, mouse β-actin was used as internal protein loading 
control. Figure shows one of at least 3 independent experiments. 
 
Fig. S3.   Effect of co-expression of hIL-3Rα SP2 and SP1 isoforms on the 
differentiation of M1 cells in response to hIL-3. Responses to hIL-3 were 
investigated in M1 cells expressing the hIL-3Rα SP1 and SP2 isoforms with hβc 
after 4 days incubation. A. FACS analysis of expression of the surface markers, 
F4/80 and Mac-1. All data are representative at least 2 independent experiments. 
B. Morphological examination by light microscopy after May-Grunwald-Giemsa 
staining. Scale bar = 20 μm. 
 
Table S1   Primers used for RT-PCR and quantitative real time PCR 
Gene Primer sequence 
F 5’-ATGGCCGCCAACCTGTGGCTC-3’  mIL-3Rα SP1 or SP2 
R 5’-GCAGGACCGAGCCGCACATCA-3’ 
F 5’-CTGTCTCCTGCAAACGAAGG-3’ hIL-3Rα SP1 and SP2 
R 5’-GTTGACGCCTGTTGGCAACG-3’ 
F 5’-GTGGGCCGCTCTAGGCACCA-3’ Mouse β-actin 
R 5’-CGGTTGGCCTTAGGGTTCAGGGGGG-3’ 
F 5’-CCTCGCCTTTGCCGATCC-3’ Human β-actin 
R 5’-GGATCTTCATGAGGTAGTCAGTC-3’ 
F 5’-CATTGGCCCCTTGTGAGGCCAG-3’ Mouse GATA-1 
R 5’-CGCTCCAGCCAGATTCGACCC-3’ 
F 5’-CGACACACCACCCGATACCCACCTAT-3’ Mouse GATA-2 
R 5’-CGCCTACGCCATGGCAGTCACCATGCT-3’ 
F 5’-GAGTTTGAGAACTTCCCTGAG-3’ Mouse PU.1 
R 5’-TGGTAGGTCATCTTCTTGCGG-3’ 
F 5’-GAGCTTGTCCAGAAATATGGTCCGAAG-3’ Mouse c-Myb 
R 5’-GGCTGCCGCAGCCGGCTGAGGGAC-3’ 
F 5’-CCAGCAAGCTGAGGAGCGGCG-3’ Mouse AML1 
R 5’-CCGACAAACCTGAGGTCGTTG-3’ 
F 5’-CACTACCTCTGGAGCACAGC-3’ Mouse Ikaros 
R 5’-TCTGAGGCATAGAGCTCTTA-3’ 
F 5’-TCAGGATCATGAAGGTCGCCAGTG-3’ Mouse Id1 
R 5’-TGAAGGGCTGGAGTCCATCTGGT-3’ 
F 5’-TGCGTCTAAGATGAGGGAGT-3’ Mouse C/EBPα 
R 5’-GATTAGGAGCCCTCCACCTC-3’ 
F 5’-CGCCCGCGCACCACGACTTCCTCT-3’ Mouse C/EBPβ 
R 5’-CGTCGCTCAGCTTGTCCACCGTCTT-3’ 
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Table S1 continued 
F 5’-CGGGCAGAGGGCGGGTCGTTCC-3’ Mouse C/EBPδ 
R 5’-GCCGGCCGCTTTGTGGTTGCTGTT-3’ 
F 5’-TGTGGCGGTGAAAGAGGAGCCT-3’ Mouse C/EBPε 
R 5’-GGCTCAGCTGCAGCCCCC-3’ 
F 5’-TGCAGCCTCTGATTGGGTTTCG-3’ Mouse NFYA 
R 5’-TCCTCCTGAGTTGACCACATTCC-3’ 
F 5’-AAGAGAATCCACAAGGAATTGAATG-3’ Mouse UBC 
R 5’-CAACAGGACCTGCTGAACACTG-3’ 
F 5’-TCGTGATTAGCGATGATGAAC-3’ Mouse HPRT 
R 5’-GCAAGTCTTTCAGTCCTGTCC-3’ 
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